APCI Endorses the Drug Price Transparency in Medicaid Act
APCI endorses bipartisan legislation to end PBM spread pricing in Medicaid, calling it a critical step toward transparency, fair reimbursement, and lower costs for patients and taxpayers.
APCI tracks and reports on pharmacy public policy developments, including PBM reform efforts, legislative activity, and regulatory changes impacting independent pharmacies.
APCI tracks and reports on pharmacy public policy developments, including PBM reform efforts, legislative activity, and regulatory changes impacting independent pharmacies.
APCI endorses bipartisan legislation to end PBM spread pricing in Medicaid, calling it a critical step toward transparency, fair reimbursement, and lower costs for patients and taxpayers.
BESSEMER, Ala. (Sept. 20) – A judge’s decision to allow the merger between UnitedHealth Group and Change Healthcare to move forward is likely to prove detrimental to patients, providers, and… Read More »
APCI urges federal regulators to block Prime Therapeutics’ acquisition of Magellan Rx, warning it would reduce competition and worsen prescription drug pricing and access.
APCI urges the FTC to investigate PBM practices, citing widespread anti-competitive behavior that drives up drug costs and limits patient access.
A new study reveals how PBMs and Part D plans increase drug costs for seniors through misaligned incentives and fees, while outlining a path to save patients billions.
APCI backs the DOJ’s move to block UnitedHealth’s acquisition of Change Healthcare, citing risks to competition, patient choice, and prescription drug pricing.
After an FTC deadlock stalls a probe into PBM practices, APCI vows to keep pushing for transparency and accountability in prescription drug pricing.
APCI warns Congress is missing a key chance to curb PBM spread pricing and reform Medicaid managed care, leaving taxpayers, patients, and community pharmacies to bear the cost.